Healing & recovery
An FDA-approved painkiller derived from cone snail venom, delivered into the spinal fluid for severe chronic pain.
Start here
Ziconotide (Prialt) is a non-opioid pain medication derived from cone snail venom, FDA approved in 2004 for severe chronic pain in adults when other treatments, including intrathecal morphine, have failed or cannot be tolerated. It is delivered by an infusion pump directly into the fluid around the spinal cord (intrathecal delivery), never into a vein, where it blocks the calcium channels that pain signals need to travel 6. It carries an FDA boxed warning for neuropsychiatric side effects and must not be used by anyone with a history of psychosis.
Ziconotide works like a natural pain-blocking substance that binds to calcium channels in your spinal cord. Calcium normally helps pain signals travel through your nerves, but ziconotide locks these channels and stops pain messages before they reach your brain. It's delivered directly into the fluid around your spinal cord through a special pump, which keeps pain relief extremely targeted without affecting your whole body.
Ziconotide is a man-made peptide of 25 amino acids (protein building blocks), copied from omega-conotoxin MVIIA, a toxin of the Conus magus cone snail. It blocks N-type voltage-gated calcium channels (Cav2.2, tiny gates that let calcium into nerve cells) on the ends of pain-sensing nerves in the superficial dorsal horn (the top layer of the back part of the spinal cord). Calcium entry is needed for nerve cells to release their chemical messengers (neurotransmitters), so blocking these channels stops pain-signaling A-delta and C fibers (types of pain nerve fibers) from passing on the signal. Pain signals are blocked at the spinal cord without switching on opioid receptors, so it can be used for pain that does not respond to opioids. Its half-life (how long it stays active in your body) in cerebrospinal fluid (the fluid around the brain and spinal cord) is about 4.6 hours, so it is given as a steady drip through an intrathecal microinfusion pump (a pump that delivers the drug into the spinal fluid).
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Pain Relief
A drug that blocks N-type calcium channels (pain-signal gates on nerve cells), delivered into the fluid around the spinal cord. It is approved for severe chronic pain in adults who need intrathecal therapy (medicine delivered into the spinal fluid) and who cannot tolerate or have not responded to other treatment, including intrathecal morphine. That last clause is the point: this is what is tried when intrathecal morphine has already failed.
Opioid Alternative
Genuinely non-opioid, and that matters. It acts on calcium channels rather than opioid receptors (the targets of morphine-type drugs), and the label states that therapy can be interrupted or stopped abruptly without evidence of withdrawal effects. Two things it does not remove: patients must NOT be abruptly withdrawn from their existing opiates but tapered over weeks and switched to an equivalent oral dose, and the label warns that patients may become unresponsive or stuporous (barely awake) on ziconotide. Trading opioid risks for a boxed neuropsychiatric warning (the label's strongest warning, about mood and thinking changes) is a trade, not an escape.
Nerve Pain
The approved indication is severe chronic pain in a refractory population rather than any specific pain syndrome, and the label does not single out neuropathic pain. The mechanism — blocking N-type calcium channels on primary nociceptive afferents in the dorsal horn — is the basis for expecting a neuropathic effect, but the indication is broader and less specific than that reasoning implies.
The most-asked question
Ziconotide (Prialt) is dose-escalated: the studies start everyone low and step the dose up on a schedule, so the right amount depends on the week you're on. The research-reported maintenance range is 2.4–19.2 mcg/day, continuous intrathecal infusion.
Starting point
2.4 mcg/day
Ziconotide is pumped directly into the fluid around the spinal cord, using an implanted or external microinfusion device — it is NOT for intravenous administration 6. The label starts at no more than 2.4 mcg per day (0.1 mcg per hour) 6. Starting low matters here more than usual: the boxed warning is for severe psychiatric symptoms and neurological impairment, and the drug is contraindicated in anyone with a history of psychosis 6.
Until pain is controlled
Increase up to 2.4 mcg/day per step
The dose is raised by up to 2.4 mcg per day at a time, no more often than 2 to 3 times a week 6. This is one of the few genuine titrations (stepping the dose up gradually) in this library: the same patient climbs the ladder, rather than different patients being assigned different rungs. What you are titrating against is not just pain — the label directs frequent monitoring for cognitive impairment, hallucinations and changes in mood or consciousness, and discontinuation if serious neurological or psychiatric signs appear 6.
Ongoing/maintenance
Up to 19.2 mcg/day
The recommended maximum is 19.2 mcg per day (0.8 mcg per hour), reached by about day 21 on the label's schedule 6. Many people settle below it. Reported psychiatric events at clinical doses include hallucinations in 12%, paranoid reactions in 3%, hostility in 2%, delirium in 2%, psychosis in 1% and manic reactions in 0.4% — and the placebo-controlled trials found a higher incidence of suicide, suicide attempts and suicidal ideation on ziconotide than on placebo 6. Slower is better tolerated than faster, and the ceiling is a ceiling, not a target.
The ceiling: 19.2 mcg/day (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Ziconotide (Prialt):
Add the recommended volume of bacteriostatic water to the Ziconotide (Prialt) vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Ziconotide (Prialt) is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Ziconotide (Prialt)'s recorded schedule.
Timing
Use Ziconotide (Prialt) at the same time each day for optimal results. Consistency in timing helps maintain stable levels and maximize therapeutic benefits. Follow your healthcare provider's specific instructions.
Ziconotide (Prialt) can generally be used with or without food. If you experience any discomfort, try taking it with a light meal. Follow specific guidance from your healthcare provider.
Ziconotide (Prialt) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Most common adverse effect reported in 46% of patients versus 13% placebo in clinical trials
What to do Usually manageable with dose adjustment; may improve with continued therapy
Reported in 40% of patients; gastrointestinal effects also include diarrhea (18%) and vomiting (16%)
What to do Antiemetic medications as needed; often improves during dose stabilization
Worth knowing about, but most people never see these.
Confusional state in 15%, amnesia in 8%, memory impairment in 7% of patients; higher rates in elderly (42% vs 29%)
What to do Dose reduction or slower titration (stepping the dose up gradually); cognitive function monitoring especially in elderly patients
Ataxia reported in 14%, nystagmus in 8%; other neurological effects include tremor and dysarthria
What to do Dose adjustment; symptoms typically reversible with dose reduction or discontinuation
Rare, but if any of these happen, stop and contact a medical professional.
Hallucinations (12%), paranoid reactions (3%), psychosis (1%), and increased suicidal ideation reported; carries FDA black box warning
What to do Immediate dose reduction or discontinuation; psychiatric evaluation; contraindicated in patients with pre-existing psychosis
40% of patients had CK above normal; 11% had CK >3x upper limit; rare cases of rhabdomyolysis with acute renal failure reported
What to do Regular CK monitoring; discontinue if symptomatic myopathy or significantly elevated CK develops
Hallucinations (12%), paranoid reactions (3%), psychosis (1%), and increased suicidal ideation reported; carries FDA black box warning for neuropsychiatric adverse reactions.
What to do Immediate dose reduction or discontinuation; psychiatric evaluation required; contraindicated in patients with pre-existing psychosis; monitor mental status closely during treatment.
Elevated creatine kinase occurs in 40% of patients; 11% have CK >3x upper limit; rare cases of rhabdomyolysis with acute renal failure and muscle breakdown have been reported.
What to do Regular CK monitoring required; discontinue if symptomatic myopathy or significantly elevated CK (>10x baseline) develops; ensure adequate hydration.
Week by week
Is it right for you?
Ziconotide (Prialt) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
May increase the slowing of the brain and nervous system (central nervous system depression), including drowsiness and confusion
Using opioids in the spinal fluid at the same time raises the risk of serious side effects, including slowed or stopped breathing (respiratory depression)
May worsen mental-health side effects, including hallucinations and the risk of psychosis (losing touch with reality)
Baclofen given into the spinal fluid (intrathecal) may complement ziconotide for conditions that combine pain and muscle stiffness (spasticity)
Gabapentin taken by mouth treats nerve pain in the limbs by also acting on calcium channels (gates that let calcium into nerve cells), in a complementary way
Rehabilitation combined with pain relief delivered into the spinal fluid (intrathecal) supports the best possible recovery of function
Generally safe to take alongside Ziconotide (Prialt). Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Ziconotide (Prialt) is particularly well-suited for individuals focused on severe chronic pain management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Ziconotide (Prialt) is particularly well-suited for individuals focused on opioid-refractory neuropathic pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Ziconotide (Prialt) is particularly well-suited for individuals focused on cancer-related intractable pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Ziconotide (Prialt) is particularly well-suited for individuals focused on reducing systemic (affecting the whole body) opioid dependence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
PRIALT carries a BOXED WARNING for neuropsychiatric adverse reactions: severe psychiatric symptoms and neurological impairment may occur, every patient must be monitored frequently for cognitive impairment, hallucinations or changes in mood or consciousness, and therapy must be discontinued if serious neurological or psychiatric signs appear. It is CONTRAINDICATED in anyone with a pre-existing history of psychosis 6. The reported rates are specific: hallucinations 12%, paranoid reactions 3%, hostility 2%, delirium 2%, psychosis 1%, manic reactions 0.4%. The label also states that ziconotide may cause or worsen depression with risk of suicide in susceptible patients, and that the placebo-controlled trials showed a HIGHER incidence of suicide, suicide attempts and suicidal ideation on ziconotide than on placebo 6. Beyond the box, the label warns about meningitis — patients and carers must know the signs, including fever, headache, stiff neck, altered mental status, nausea or vomiting and occasionally seizures — about patients becoming unresponsive or stuporous, about elevations in creatine kinase requiring periodic monitoring, and about opiate withdrawal: patients must NOT be abruptly withdrawn from their opiates but tapered over a few weeks and replaced with an equivalent oral dose 6. Ziconotide itself can be stopped abruptly without withdrawal effects 6.
Every figure above comes from the PRIALT prescribing information, which is the primary document for this compound 6. The rates the page previously carried — mood changes in '20-50% of patients depending on infusion rate' and cognitive decline requiring dose reduction in 'about 25%' — did not come from the label and had no source attached. Ziconotide's approved population is narrow: adults with severe chronic pain for whom intrathecal therapy is already warranted and who are intolerant of or refractory to other treatment, including intrathecal morphine 6. It requires an implanted or external pump and a physician experienced in intrathecal administration; nothing about it is self-administered.
Keeping it good
Store Ziconotide (Prialt) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Ziconotide (Prialt) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2025
A meta-analysis (a combined analysis of many studies) of ziconotide showed significant pain reduction (22.54-point improvement) versus placebo, with 17.85% serious adverse events (serious side effects). Secondary results suggest it may reduce the need for opioids, though the quality of evidence was moderate.
Picañol J, et al.
2025
Five patients successfully cut their morphine dose by 50% after 6 weeks of slowly raising ziconotide, while pain fell from 8.0 to 2.5. Nerve-pain symptoms improved dramatically, with an 80% reduction in tingling.
Canovas Martínez L, et al.
2026
A narrative review (an expert overview of the research) established ziconotide as a selective Cav2.2 channel blocker (it blocks one specific type of calcium gate on nerve cells), offering precise pain relief by delivery into the spinal fluid (intrathecal) for refractory chronic pain (pain that does not respond to other treatments). Combined with morphine, it reduced opioid requirements.
Wahezi S, et al.
2025
No abstract available for comprehensive analysis.
Gan H, et al.
2025
No abstract available for comprehensive analysis.
Noe G, et al.
2023
PRIALT is given only by intrathecal infusion (a slow drip into the fluid around the spinal cord). Start at no more than 2.4 mcg/day (0.1 mcg/hr) and raise the dose in steps of up to 2.4 mcg/day, no more than 2 to 3 times per week, based on response and side effects, up to a maximum of 19.2 mcg/day (0.8 mcg/hr).
TerSera / U.S. FDA
If this isn't the right fit
Your questions
Ziconotide works through a completely different mechanism than opioids. It blocks N-type calcium channels at the spinal cord rather than activating opioid receptors. This means it does not cause respiratory depression, does not produce tolerance or physical dependence, and cannot be reversed by naloxone. It provides an alternative for patients who have failed opioid therapy.
Ziconotide is a large peptide (25 amino acids) that cannot cross the blood-brain barrier when given systemically (affecting the whole body). Intrathecal delivery places the drug directly into the cerebrospinal fluid where it can access its target calcium channels on spinal cord neurons. This route also minimizes systemic side effects while maximizing spinal cord concentrations.
Ziconotide carries a black box warning for neuropsychiatric adverse reactions. Patients may experience severe psychiatric symptoms including hallucinations, psychosis, paranoid reactions, and changes in mental status. It is contraindicated in patients with a pre-existing history of psychosis. Cognitive impairment and reduced consciousness may also occur.
Ziconotide should be used cautiously with other intrathecal agents. While some practitioners combine it with intrathecal baclofen for mixed pain and spasticity, concurrent use with intrathecal opioids may increase the risk of serious adverse events. The drug should not be mixed with other medications in the same pump reservoir without compatibility data.
Pain relief may begin within hours of starting the intrathecal infusion, as the drug's CSF half-life (how long it stays active in your body) is approximately 4.6 hours. However, optimal pain relief typically requires a gradual titration (stepping the dose up gradually) period of 1-3 weeks, during which the dose is carefully increased based on individual response and tolerability.
The programmable infusion pump requires periodic refills every 40-84 days depending on the drug concentration used and flow rate. Pump battery replacement surgery is needed approximately every 5-7 years. Regular follow-up visits are essential for dose adjustments, pump monitoring, and screening for catheter-related complications including infection.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Ziconotide (Prialt) research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Talk to a clinician before taking anything.
PeptideGeek